September 2023
New Publication in The Lancet Diabetes & Endocrinology

Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are statistically defined by the 2·5-97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define the optimal healthy ranges of TSH and FT4 based on the risk of cardiovascular disease and mortality.

February 2022
New Publication in Frontiers in Psychiatry

In non-randomized studies (NRSs) where a continuous outcome variable (e.g., depressive symptoms) is assessed at baseline and follow-up, it is common to observe imbalance of the baseline values between the treatment/exposure group and control group. This may bias the study and consequently a meta-analysis (MA) estimate. These estimates may differ across statistical methods used to deal with this issue. Analysis of individual participant data (IPD) allows standardization of methods across studies. 

September 2022
New publication in European Journal of Endocrinology

 Few prospective studies have assessed whether persons with subclinical thyroid dysfunction are more likely to develop diabetes, with conflicting results. We conducted a systematic review of the literature and an individual participant data analysis of multiple prospective cohorts to investigate the association between subclinical thyroid dysfunction and incident diabetes.

November 2021
New Publication in JAMA Internal Medicine

Thyroid dysfunction is considered a potentially reversible cause of cognitive decline; hence, thyroid function screening tests are described in guidelines as an essential component of the workup for the diagnosis of dementia.1-3 Thyroid dysfunction is frequently observed in individuals with suspected dementia. However, the outcomes of treatment of overt hypothyroidism and hyperthyroidism and subclinical hyperthyroidism on cognitive function are not fully clarified. For subclinical hypothyroidism, 4 of 5 recent randomized clinical trials and a meta-analysis on levothyroxine treatment did not find evidence for an improvement in cognitive function.

June 2019
New Publication in BMJ OPEN

Prospective cohort studies on the association between subclinical thyroid dysfunction and depressive symptoms have yielded conflicting findings, possibly because of differences in age, sex, thyroid-stimulating hormone cut-off levels or degree of baseline depressive symptoms. Analysis of individual participant data (IPD) may help clarify this association.